Allergan already has a name for the combination of Botox, dermal fillers and Kybella: the liquid facelift.

Interested in chin filler? Here's my review after testing, plus all the FAQs from experts on cost, pain, what to expect, and how long it lasts in 2024.

Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin".

Double chin got you down? There's now a shot for that. The Food and Drug Administration on Wednesday approved a new treatment for adults with "moderate-to-severe fat" below the chin, known as ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. While submental fat (aka neck fat or double chin) is perfectly normal due to ...

This spring, the Food and Drug Administration approved Kybella, an injectable deoxycholic-acid treatment designed to eliminate “submental fat”—known to the rest of us as a double chin (or an “at-risk ...

The maker of Botox is looking to eliminate the double chin with a new drug.

The brains behind Botox have taken notice. Allergan, the pharmaceutical company that owns the wrinkle-smoothing drug, is set to acquire Kythera Biopharmaceuticals this week for $2.1 billion.

Is this the next botox? Vancouver at the leading edge of a fat-melting treatment for double chins David Tedham isn’t, in the parlance of the multi-billion-dollar global cosmetic industry, a ...

Double chins may not be big business yet but Allergen PLC -- which makes Botox -- is betting they soon will be. Our chins aren't getting any younger, after all. Allergen is paying about $2.1 ...

FDA Approves Double-Chin Shot The U.S. Food and Drug Administration has approved an injection designed specifically to reduce unsightly double chins.